Results of a post hoc analysis of 3 phase 3 trials of tolebrutinib suggest that PRLs are associated with an increased risk for disability accumulation in MS.
The post Paramagnetic Rim Lesions Predict Effectiveness of Tolebrutinib first appeared on Physician’s Weekly.
